Local recurrence and local control of non-metastatic osteosarcoma of the extremities: A 27-year experience in a single institution

Journal of Surgical Oncology

Volumn 96, Issue 2, 2007, Pages 118-123

  Bacci, Gaetano ^a   Forni, Cristiana ^a   Longhi, Alessandra ^a   Ferrari, Stefano ^a   Mercuri, Mario ^a   Bertoni, Franco ^a   Serra, Massimo ^a   Briccoli, Antonio ^a   Balladelli, Alba ^a   Picci, Piero ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Local control; Local recurrence; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LIMB AMPUTATION; LIMB SALVAGE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SURGICAL RISK; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AMPUTATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DRUG ADMINISTRATION SCHEDULE; EXTREMITIES; FEMALE; HUMANS; LIMB SALVAGE; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 34547945108     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20628     Document Type: Article

References (23)

1. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;153:106-120.
2. Campanacci M, Laus M: Local recurrence after amputation for osteosarcoma. J Bone Joint Surg Br 1980;62-B:201-207.
3. Simon MA, Aschliman MA, Thomas N, et al.: Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am 1986;68:1331-1337.
4. Picci P, Sangiorgi L, Bahamonde L, et al.: Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol 1997;8:899-903.
5. Bielack SS, Kempf-Bielack B, Winkler K: Osteosarcoma: Relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 1996;14:683-684.
6. Grimer RJ, Sommerville S, Warnock D, et al.: Management and outcome after local recurrence of osteosarcoma. Eur J Cancer 2005;41:578-583.
7. Weeden S, Grimer RJ, Cannon SR, et al.: The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 2001;37:39-46.
8. Rodriguez-Galindo C, Shah N, McCarville MB, et al.: Outcome after local recurrence of osteosarcoma: The St. Jude Children's Research Hospital experience (1970-2000). Cancer 2004;100:1928-1935.
9. Bacci G, Ferrari S, Mercuri M, et al.: Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand 1998;69:230-236.
10. Campanacci M, Bacci G, Bertoni F, et al.: The treatment of osteosarcoma of the extremities: Twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer 1981;48:1569-1581.
11. Bacci G, Gherlinzoni F, Picci P, et al.: Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: A randomized study. Eur J Cancer Clin Oncol 1986;22:1337-1345.
12. Bacci G, Picci P, Ruggieri P, et al.: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990;65:2539-2553.
13. Bacci G, Picci P, Ferrari S, et al.: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993;72:3227-3238.
14. Ferrari S, Mercuri M, Picci P, et al.: Nonmetastatic osteosarcoma of the extremity: Results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 1999;85:458-464.
15. Bacci G, Ferrari S, Longhi A, et al.: High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002;14:198-206.
16. Picci P, Bacci G, Campanacci M, et al.: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985;56:1515-1521.
17. Rosen G, Caparros B, Huvos AG, et al.: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-1230.
18. Grimer RJ, Taminiau AM, Cannon SR: Surgical outcomes in osteosarcoma. J Bone Joint Surg Br 2002;84:395-400.
19. Bacci G, Ferrari S, Lari S, et al.: Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br 2002;84:88-92.
20. Lindner NJ, Ramm O, Hillmann A, et al.: Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin Orthop Relat Res 1999;358:83-89.
21. Sluga M, Windhager R, Lang S, et al.: Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop Relat Res 1999;358:120-127.
22. Winkler K, Bieling P, Bielack S, et al.: Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop Relat Res 1991;270:79-86.
23. Brosjo O: Surgical procedure and local recurrence in 223 patients treated 1982-1997 according to two osteosarcoma chemotherapy protocols. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl 1999;285:58-61.